Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
2024

Palinopsia Linked to Ribociclib in Breast Cancer Treatment

Sample size: 2 publication Evidence: low

Author Information

Author(s): Martos Tamara, Saint-Gerons Marta, Masfarre Laura, Castro-Henriques Maria, Martinez-Garcia Maria, Servitja Sonia, Albanell Joan

Primary Institution: Hospital del Mar, Parc de Salut Mar, Barcelona, Spain

Hypothesis

Can ribociclib cause palinopsia in patients with metastatic breast cancer?

Conclusion

Ribociclib may be associated with palinopsia, a rare visual disturbance, in patients undergoing treatment for metastatic breast cancer.

Supporting Evidence

  • Palinopsia was observed in both patients during ribociclib therapy.
  • Neuro-ophthalmological assessments showed no organic cause for the visual disturbances.
  • Symptoms of palinopsia were time- and dose-dependent with ribociclib intake.

Takeaway

Some patients taking ribociclib for breast cancer might see things that aren't there, but it usually goes away when they stop the medicine.

Methodology

Case reports of two patients experiencing palinopsia during ribociclib treatment, with neuro-ophthalmological assessments and brain MRIs conducted.

Potential Biases

Potential bias in reporting due to the small sample size and reliance on patient self-reports.

Limitations

The study is based on only two case reports, limiting generalizability.

Participant Demographics

Two female patients, one aged 46 and the other 28, both with HR-positive, HER2-negative metastatic breast cancer.

Digital Object Identifier (DOI)

10.3389/fonc.2024.1430341

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication